Updates from American Society for Blood and Marrow Transplantation (ASBMT) Annual Meeting Webinar
May 17, 2018
5:00 – 6:00 pm Central
Credits: 1 hour BCOP and/or 1 hour ACPE
BCOP credits are available to earn until November 13, 2018
Individual webinar pricing: $40 (member) / $70 (non-member)
This may also be purchased as part of the 2018 BCOP Webinar Bundle.
HOPA is pleased to present the second of a five-webinar series, which will review key findings from clinical and translational research, and data presented at national oncology meetings.
- Examine relevant research on transplants or cellular therapies in the treatment of multiple myeloma, myelodysplastic syndrome, leukemia, and lymphoma presented at the 2018 Tandem meeting.
- Assess relevant research on allogeneic, autologous, and haploidentical transplantation presented at the 2018 Tandem meeting.
- Evaluate novel drugs and their utility as presented at the 2018 Tandem meeting in graft versus host disease (GVHD)and/or the malignancies described above.
Dr. Rebecca Tombleson, PharmD BCOP
Dr. Rebecca Tombleson is a Board Certified Oncology Pharmacist. She currently practices as a clinical pharmacist in the Blood and Marrow Transplantation Department of Moffitt Cancer Center where she completed her PGY2 training in oncology in 2010.
Disclosure: No financial relationships exist with commercial interests.
This activity is intended for intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 1 contact hour (.1 CEUs) under the ACPE universal activity number 0465-0000-18-053-H04-P.
The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. An ACPE statement of credit will be issued only upon completion of the pre/post- assessment and a post-activity evaluation form. The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Board of Pharmacy Specialties (BPS) as a provider of board certification oncology credit (BCOP). A BCOP statement of credit will be issued only upon completion of a post-activity evaluation form and posttest, with a passing grade of 75% achieved. BCOP test must be completed by November 13, 2018.
The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Board of Pharmacy Specialties (BPS) as a provider of board certification oncology credit (BCOP). A BCOP statement of credit will be issued only upon completion of a post-activity evaluation form and posttest, with a passing grade of 75% achieved. Test must be completed by November 13, 2018.
Disclosure of Conflicts of Interest: The Hematology/Oncology Pharmacy Association (HOPA) assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CE activities. All relevant conflicts of interest that are identified are thoroughly vetted by HOPA for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. HOPA is committed to providing its learners with high-quality CE activities and related materials that promote improvements of quality in healthcare and not a specific proprietary business interest of a commercial interest.
Reported Areas of Conflict: Planners and Managers Hematology/Oncology Pharmacy Association does not view the existence of relationships as an implication of bias or that the value of the material is decreased. The content of the activity was planned to be balanced, objective, and scientifically rigorous. Occasionally, authors may express opinions that represent their own viewpoint. Conclusions drawn by participants should be derived from objective analysis of scientific data. Unlabeled/unapproved uses of drugs. All faculty have indicated that they have not referenced unlabeled/unapproved uses of drugs and devices.